$ATEX

YAZDI MAHVASH sold $560K of ATEX

YAZDI MAHVASH sold 7,000 shares of Anterix Inc. (ATEX) at $80.00 ($0.56M total) on 2026-06-16.

Original reporting
SEC EDGAR · YAZDI MAHVASH
Published Jun 17, 2026, 11:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATEX
Neutral
high confidence
Mentioned
$ATEX
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXNeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale details (shares, price, total value, post-transaction holdings).

02

Market read

Traders may monitor ATEX for sentiment effects from insider selling, but the disclosure alone is unlikely to drive a durable repricing.

03

What to watch

The filing doesn’t state motives, and the remaining holdings (19,407 shares) suggest the director didn’t exit the position.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-17 (after 2026-06-16 sale)

Background

SEC Form 4 reports insider transactions for Anterix Inc. (ATEX).

Company-level read

Ticker impact

$ATEXNeutralHigh confidence
Context

Anterix (ATEX) disclosed via Form 4 that director Yazdi Mahvash sold 7,000 shares at $80/share for ~$560k on 2026-06-16.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless paired with other disclosures.

Evidence & confidence

The filing is a Form 4 insider sale with no 10b5-1 plan and no accompanying company-specific operational/regulatory catalyst in the text.

Market effects

Minimal; this is a single-company insider transaction with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

Without a 10b5-1 plan, the sale could still be non-informational (tax/liquidity), so the market may overreact.

Key entities

  • Anterix Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Yazdi Mahvash

    Director who sold 7,000 shares at $80/share.

Related articles

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2